Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care
-
Published:2023-12
Issue:
Volume:38
Page:101794
-
ISSN:1936-5233
-
Container-title:Translational Oncology
-
language:en
-
Short-container-title:Translational Oncology
Author:
Xiao Yao,
Li Zi-Zhan,
Zhong Nian-Nian,
Cao Lei-Ming,
Liu Bing,
Bu Lin-LinORCID
Subject
Cancer Research,Oncology
Reference88 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018
2. Delivery technologies for cancer immunotherapy;Riley;Nat. Rev. Drug Discov.,2019
3. The immune checkpoint inhibitors: where are we now?;Webster;Nat. Rev. Drug Discov.,2014
4. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J. Clin. Oncol.,2010
5. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study;Lynch;J. Clin. Oncol.,2012